BTHE

Boston Therapeutics Inc

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 3/08/2017
Contact Info
  • 1750 Elm Street
  • Manchester, NH 03104

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001473579
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2009
Employees 6 a/o Mar 07, 2017
Company Officers/Contacts
Carl Rausch CEO
Stephen Spanos Consultant
Company Directors
Conroy Cheng
S. Colin Neill
Carl Rausch
Service Providers
Accounting/Auditing Firm
Liggett & Webb, P.A
1500 Gateway Blvd
Suite 202
Boynton Beach, FL, 33426
United States
 
Securities Counsel
Fleming PLLC
49 Front Street.
Suite 206
Rockville Centre, NY, 11570
United States
 
Investor Relations Firm

Not Available
BTHE Security Details
Share Structure
Market Value1 $2,802,170 a/o Mar 24, 2017
Authorized Shares 400,000,000 a/o Mar 07, 2017
Outstanding Shares 46,702,836 a/o Mar 07, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 34,292,501 a/o Mar 07, 2017
Par Value 0.001
Transfer Agent(s)
Worldwide Stock Transfer, LLC
Shareholders
Shareholders of Record 1,820 a/o Mar 07, 2017
Short Selling Data
Short Interest 3,000 (76.47%)
Feb 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security